Trastuzumab duocarmazine

Trastuzumab duocarmazine ((vic) -Trastuzumab duocarmazine) is a HER2-targeting ADC that is recognized and cleaved by histone B in tumor cells and selectively targets tumor cells. Trastuzumab duocarmazine has anti-tumor activity and can be used in cancer research related to uterine and ovarian sarcomas[1].

Product Specifications

CAS Number

[1642152-40-6]

Product Name Alternative

(vic) -Trastuzumab duocarmazine

UNSPSC

12352203

Target

Antibody-Drug Conjugates (ADCs)

Type

ADC Related

Related Pathways

Antibody-drug Conjugate/ADC Related

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/trastuzumab-duocarmazine.html

Purity

99.87

Solubility

10 mM in DMSO

Smiles

[Trastuzumabduocarmazine]

Molecular Weight

149000 (average)

References & Citations

[1]Gulden Menderes, et al. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. Clin Cancer Res. 2017 Oct 1;23 (19) :5836-5845.